Biochem/physiol Actions

Sulopenem, formerly CP-70,429, is stable to renal dehydropeptidase I and hydrolytic activity of AmpC β-lactamases and extended-spectrum β-lactamases (ESBLs) that convey resistance to third-generation cephalosporins. This action of sulopenem helps to act against urgentdrug-resistant antimicrobial threats, including ESBL-producing Enterobacteriaceae. Sulopenem is effective than ciprofloxacin for treating urogenital upper urinary tract infection (uUTI) in adult women due to quinolone non-susceptible pathogens.

Sulopenem is an orally available penem antibiotic designed to treat Gram-negative multi-drug resistant infections. It can be administered as an intravenous preparation, and it is also orally available.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.